Evidence map›Paper›PMID 26828774›Full record

ReviewBiochimica et biophysica acta2016

Carnitine transport and fatty acid oxidation.

Nicola Longo, Marta Frigeni, Marzia Pasquali

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04149717 (The Effect of Energy Drink Ingredients on Cardiovascular Function), which is not on this map. Cited by 511 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
511citing papers in PubMed, 1 pooled it
28.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04149717 naunknown statusnot on this mapstarted 2020, after this paper: background citation

The Effect of Energy Drink Ingredients on Cardiovascular Function

TypeinterventionalSponsorDuquesne UniversityRan2020 to 2023Enrolled35ConditionsCardiac Arrhythmia, Blood PressureArmsEnergy Drink Ingredients and Exercise
3 · Its place in the literature

Who cites it

511 citing papers in PubMed, 1 synthesis or guideline pooled it, 919 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Nutrients · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

451 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nicola LongoDivision of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA; Department of Pathology, University of Utah, and ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT, USA. Electronic address: Nicola.Longo@hsc.utah.edu.
Marta FrigeniDivision of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Marzia PasqualiDepartment of Pathology, University of Utah, and ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT, USA.
University of Utah · US

Funding

THE CARNITINE TRANSPORTER IN HUMAN DISEASER01DK053824 · NIDDK · UNIVERSITY OF UTAH · PI LONGO, NICOLA · 2000 to 2010
$2.3M
NIDDK NIH HHS R01 DK053824
6 · The paper itself

Abstract

Carnitine is essential for the transfer of long-chain fatty acids across the inner mitochondrial membrane for subsequent β-oxidation. It can be synthesized by the body or assumed with the diet from meat and dairy products. Defects in carnitine biosynthesis do not routinely result in low plasma carnitine levels. Carnitine is accumulated by the cells and retained by kidneys using OCTN2, a high affinity organic cation transporter specific for carnitine. Defects in the OCTN2 carnitine transporter results in autosomal recessive primary carnitine deficiency characterized by decreased intracellular carnitine accumulation, increased losses of carnitine in the urine, and low serum carnitine levels. Patients can present early in life with hypoketotic hypoglycemia and hepatic encephalopathy, or later in life with skeletal and cardiac myopathy or sudden death from cardiac arrhythmia, usually triggered by fasting or catabolic state. This disease responds to oral carnitine that, in pharmacological doses, enters cells using the amino acid transporter B(0,+). Primary carnitine deficiency can be suspected from the clinical presentation or identified by low levels of free carnitine (C0) in the newborn screening. Some adult patients have been diagnosed following the birth of an unaffected child with very low carnitine levels in the newborn screening. The diagnosis is confirmed by measuring low carnitine uptake in the patients' fibroblasts or by DNA sequencing of the SLC22A5 gene encoding the OCTN2 carnitine transporter. Some mutations are specific for certain ethnic backgrounds, but the majority are private and identified only in individual families. Although the genotype usually does not correlate with metabolic or cardiac involvement in primary carnitine deficiency, patients presenting as adults tend to have at least one missense mutation retaining residual activity. This article is part of a Special Issue entitled: Mitochondrial Channels edited by Pierre Sonveaux, Pierre Maechler and Jean-Claude Martinou.

Indexed as

AdultAge of OnsetBiological TransportCarnitineCaveolinsEnergy MetabolismFastingFatty Acid-Binding ProteinsFatty AcidsFatty Acid Transport ProteinsHumansInfant, NewbornKidneyMutationNeonatal ScreeningOrganic Cation Transport ProteinsCarnitineCaveolinsFatty Acid-Binding ProteinsFatty AcidsFatty Acid Transport ProteinsOrganic Cation Transport ProteinsSLC22A5 protein, humanSolute Carrier Family 22 Member 5ArrhythmiaAutismCarnitineNewborn screeningOCTN2SLC22A5

Identifiers

PMID26828774
PMCPMC4967041
OpenAlexW2290337523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.